摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-naphthylmethyl)-5-(4-piperidyl)isothiazol-3-ol hydrobromide

中文名称
——
中文别名
——
英文名称
4-(2-naphthylmethyl)-5-(4-piperidyl)isothiazol-3-ol hydrobromide
英文别名
4-(Naphthalen-2-ylmethyl)-5-piperidin-4-yl-1,2-thiazol-3-one;hydrobromide
4-(2-naphthylmethyl)-5-(4-piperidyl)isothiazol-3-ol hydrobromide化学式
CAS
——
化学式
BrH*C19H20N2OS
mdl
——
分子量
405.359
InChiKey
QAIGFYPCANGEDP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.23
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    66.4
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TREATING NEUROMUSCULAR OR NEUROLOGIC DISEASE THROUGH REDUCING GABAERGIC AND/OR GLYCINERGIC INHIBITORY NEUROTRANSMITTER OVERSTIMULATION<br/>[FR] TRAITEMENT DE MALADIE NEUROMUSCULAIRE OU NEUROLOGIQUE PAR RÉDUCTION DE LA SURSTIMULATION DES NEUROTRANSMETTEURS INHIBITEURS GABAERGIQUES ET/OU GLYCINERGIQUE
    申请人:RY PHARMA B V
    公开号:WO2016114655A1
    公开(公告)日:2016-07-21
    The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pharmaceutical compositions comprising one or more compounds capable of reducing Glycinergic activity and/or one or more compounds capable of reducing GABAergic activity are also provided. Methods for treating one or more symptoms caused by inhibitory neurotransmitter overstimulation (e.g., muscle wasting, loss of muscle function, loss of muscle coordination, respiratory depression, dysphagia, dysarthria, eye movement difficulties, oculomotor gaze palsy, supranuclear gaze palsy, bladder dysfunction and gastrointestinal dysfunction) in an individual afflicted with ALS or an ALS- like disorder are also provided.
  • Potent 4-Arylalkyl-Substituted 3-Isothiazolol GABA<sub>A</sub> Competitive/Noncompetitive Antagonists:  Synthesis and Pharmacology
    作者:Dorte Krehan、Signe í Storustovu、Tommy Liljefors、Bjarke Ebert、Birgitte Nielsen、Povl Krogsgaard-Larsen、Bente Frølund
    DOI:10.1021/jm050987l
    日期:2006.2.1
    The GABA(A) agonists muscimol (1), 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP, gaboxadol, 3), and the partial GABA(A) agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 6a) and their respective 3-isothiazolol analogues thiomuscimol (2), thio-THIP (4), and thio-4-PIOL (7a) are ligands at the GABA(A) orthosteric (recognition) site. The structure-activity relationships (SARs) between these structures
    GABA(A)激动剂muscimol(1),4,5,6,7-四氢异恶唑[5,4-c]吡啶-3-醇(THIP,gaboxadol,3)和部分GABA(A)激动剂5- (4-哌啶基)-3-异唑醇(4-PIOL,6a)及其各自的3-异噻唑醇类似物thiomuscimol(2),thio-THIP(4)和thio-4-PIOL(7a)是GABA( A)正构(识别)部位。这些结构之间的构效关系(SAR)是GABA(A)激动剂和竞争性拮抗剂的3D药效团模型的关键元素[Frolund,B .; 约根森(AT);Tagmose,L .; TB,Stensbol;HT,Vestergaard;Engblom,C .;美国,克里斯蒂安森;桑切斯 Krogsgaard-Larsen,P .;Liljefors,TJ Med。化学 2002,45,2454-2468]。在此模型的提示下,我们现在报告一系列7a类似
查看更多